- Home
- CANF vs JZXN Comparison
CANF vs JZXN Comparison
Compare CANF & JZXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CANF | JZXN |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | Israel | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8M | 16.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CANF | JZXN |
|---|---|---|
| Price | $0.25 | $1.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 665.4K |
| Earning Date | 02-03-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $560,000.00 | $97,465.00 |
| Revenue This Year | $461.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.25 | $1.85 |
| 52 Week High | $2.33 | $312.80 |
Technical Indicators
Market Signals| Indicator | CANF | JZXN |
|---|---|---|
| Relative Strength Index (RSI) | 30.40 | 55.67 |
| Support Level | $0.26 | $2.12 |
| Resistance Level | $0.30 | $2.78 |
| Average True Range (ATR) | 0.02 | 0.80 |
| MACD | -0.00 | 0.12 |
| Stochastic Oscillator | 2.09 | 21.51 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.